Form 4: Cassava Sciences Chief Medical Officer Granted Stock Options

James William Kupiec, Chief Medical Officer of Cassava Sciences, was granted stock options for 10,000 shares on May 20, 2024.

Summary

• James William Kupiec, the Chief Medical Officer of Cassava Sciences, was granted stock options on May 20, 2024.
• The options are for 10,000 shares of Cassava Sciences common stock.
• The exercise price of the options is $22.10 per share.
• The options vest over four years, at a rate of 1/48th each month, and expire on May 20, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact sentiment.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• The vesting schedule of four years is also typical.
• Comparing the size of the grant to similar companies would require further analysis of executive compensation packages in the sector.

Stakeholder Impact

• The stock option grant could potentially incentivize the Chief Medical Officer to improve the company's performance, which would benefit shareholders.

Key Dates